Fiche publication
Date publication
avril 2016
Journal
Medecine sciences : M/S
Auteurs
Membres identifiés du Cancéropôle Est :
Pr GHIRINGHELLI François
,
Dr VEGRAN Frédérique
Tous les auteurs :
Vegran F, Martin F, Apetoh L, Ghiringhelli F
Lien Pubmed
Résumé
Th9 cells are CD4 T helper cells characterized by their ability to produce IL-9 and IL-21. These cells are obtained from naive CD4(+) T cells cultured in the presence of TGF-β and IL-4. Thus their differentiation results from the balance between the signaling pathways induced by IL-4 in one hand and the one induced by TGF-β in the other hand. These cells are inflammatory cells and were first described in the context of atopic and autoimmune diseases in which they have a pathogenic role. They are also involved in the defense against parasite infections. Recently, some reports defined Th9 anticancer properties through their cytokine secretion. Indeed, their high secretion of IL-9 and IL-21 in the tumor bed contributes to their anticancer functions. These cytokines trigger the activation of dendritic cells, mast cells, natural killer cells, and CD8 T cells to mount an antitumor immune response.
Mots clés
Animals, Antineoplastic Agents, metabolism, Humans, Immunotherapy, Adoptive, Interleukin-9, metabolism, Lymphocytes, Tumor-Infiltrating, immunology, Neoplasms, immunology, T-Lymphocytes, Helper-Inducer, metabolism, Tumor Microenvironment
Référence
Med Sci (Paris). 2016 Apr;32(4):387-93
